RNS® System Epilepsy PAS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02403843|
Recruitment Status : Active, not recruiting
First Posted : March 31, 2015
Last Update Posted : April 1, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Epilepsy||Device: RNS System|
NeuroPace, Inc. is sponsoring a post-approval study (PAS) of the RNS System device. The RNS System is the first FDA-approved closed loop responsive neurostimulator designed to reduce the frequency of seizures in individuals with partial onset seizures.
The RNS System Epilepsy PAS is a 5 year, non-randomized, open-label, multi-center prospective observational study. Data regarding safety and efficacy are collected at enrollment and periodically throughout the 5-year study.
The study is designed to assess the long-term safety and effectiveness of the RNS System as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures (motor partial seizures, complex partial seizures and/or secondarily generalized seizures).
Data from the RNS System Epilepsy PAS will be used to calculate long-term SAE rates, median percent change in seizure frequency (from pre-implant retrospective data), as well as other safety and effectiveness endpoints.
|Study Type :||Observational|
|Estimated Enrollment :||375 participants|
|Official Title:||RNS® System Post-Approval Study in Epilepsy|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||May 2023|
|Estimated Study Completion Date :||May 2023|
A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
Device: RNS System
The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
- SAE rate [ Time Frame: Implant through 5 years post-implant ]Calculate annual SAE rates over time in the entire subject population as well as within subpopulations.
- Neurosurgeon experience [ Time Frame: Implant through 41 days post-implant ]Demonstrate there is no difference in safety in 6-week perioperative period based on the experience of NeuroPace qualified and trained implanting physicians.
- Physician experience [ Time Frame: Implant through 1 year post-implant ]Demonstrate there is no difference in safety 1 year post-implant based on experience of NeuroPace qualified and trained treating physicians and Comprehensive Epilepsy Centers.
- Product use - surgical proceduresPresent the incidence and number of AEs related to surgical procedures associated with implant, explant, reimplantation, and revision of the neurostimulator and lead(s).
- AutopsyPresent data from autopsies obtained from any patient implanted with neurostimulator/leads.
- Median percentage reduction in disabling seizure [ Time Frame: Pre-implant (retrospective data) compared to 30 to 36 months post-implant ]Demonstrate that the median percentage reduction in disabling seizures over time in the entire subject population is comparable to the median percentage reduction in disabling seizures over time in the LTT study. Characterize the median percentage reduction in disabling seizures over time within subpopulations.
- Neurostimulator programming [ Time Frame: Through 5 years post-implant ]Demonstrate that stimulation programming classes have similar effects on the overall seizure frequency.
- Seizure worsening [ Time Frame: 6 months post-implant through 36 months post-implant ]Demonstrate that there is not a worsening in disabling seizures over time in the entire subject population. Assess the sustained effect on disabling seizure frequency over time within subpopulations.
- Neurostimulator programming [ Time Frame: Implant through 5 years post-implant ]Characterize the effects of stimulation programming classes on the overall 5-year rate of SAEs and device-related non-serious AEs.
- Neurostimulator battery longevityCharacterize the clinically observed battery longevity over time and in relation to therapy load in patients treated with the RNS System.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
A clinical decision to treat the patient with the RNS System in accordance with its approved indication for use has been made prior to enrollment in the study. For approved indication for use and contraindications, refer to current physician labeling and instructions for use (manuals) for the RNS System available at the NeuroPace website (www.neuropace.com).
This post-approval study also has the following additional study related inclusion criteria:
- Subject or legal guardian is able to provide appropriate consent to participate
- Subject is able to maintain a seizure diary alone or with the assistance of a competent individual
- Subject is able to attend clinic appointments in accordance with the study schedule
Per clinician assessment, treatment with the RNS System is contraindicated based on current RNS System labeling. For approved indication for use and contraindications, refer to current physician labeling and instructions for use (manuals) for the RNS System available at the NeuroPace website (www.neuropace.com).
This post-approval study has the following additional study related exclusion criteria:
- Subject is participating in a therapeutic investigational drug or device study
- Subject was treated with a VNS within the last three months (90 days)
- Subject is pregnant
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02403843
|Study Director:||Martha J Morrell, MD||NeuroPace, Inc.|
|Other Study ID Numbers:||
PMA100026 ( Other Identifier: United States FDA )
|First Posted:||March 31, 2015 Key Record Dates|
|Last Update Posted:||April 1, 2022|
|Last Verified:||March 2022|
Central Nervous System Diseases
Nervous System Diseases